Jeremy Pearlman

Jeffrey Cohen

- STRATA Skin Sciences announced a clinical case study demonstrating the successful use of its **XTRAC 308-nm excimer laser** to treat poikilodermatous mycosis fungoides (pMF), a rare subtype of cutaneous T-cell lymphoma.  **[1051514_a64ecbce27f34646b96d1b77a9f56f5d_0]** 
- This peer-reviewed study, published in *Case Reports in Oncology*, represents the **first English-language report** validating excimer laser therapy as a safe and effective option for this difficult-to-treat condition.  **[1051514_a64ecbce27f34646b96d1b77a9f56f5d_0]** 
- The company's President and CEO noted that the Centers for Medicare and Medicaid Services (CMS) have **significantly expanded reimbursement codes** for a wider variety of inflammatory skin conditions, including MF and pMF, due to the XTRAC's versatility.  **[1051514_a64ecbce27f34646b96d1b77a9f56f5d_0]** 
- A 2022 systematic review also concluded that the 308-nm excimer laser is a safe and effective treatment for early-stage mycosis fungoides, with **73.6% of patients achieving a complete clinical response**.  **[1051514_a64ecbce27f34646b96d1b77a9f56f5d_1]**

STRATA Skin Sciences Announces Positive Clinical Study for XTRAC Excimer Laser in Rare Lymphoma Subtype

- STRATA Skin Sciences highlights the **XTRAC® Excimer Laser** as a safe and highly effective treatment for localized atopic dermatitis, supported by peer-reviewed clinical evidence.  **[1051514_3f574e2500bd48248c3bd92f03175b46_0]** 
- The **American Medical Association (AMA)** has expanded excimer laser's indications to inflammatory and autoimmune skin diseases, clearing the way for Medicare, Medicaid, and private payer reimbursement for atopic dermatitis treatment.  **[1051514_3f574e2500bd48248c3bd92f03175b46_0]** 
- Clinical studies demonstrate the XTRAC® Excimer Laser's efficacy, with one study showing a **69% reduction in disease severity** and **87% of patients achieving clear or almost clear skin** for severe chronic hand and foot eczema.  **[1051514_3f574e2500bd48248c3bd92f03175b46_1]** 
- The XTRAC® Excimer Laser offers benefits such as **targeted therapy**, effectiveness for difficult areas, lower UV exposure, convenience, and being **steroid-sparing**.  **[1051514_3f574e2500bd48248c3bd92f03175b46_2]**

STRATA Skin Sciences Highlights XTRAC® Excimer Laser for Atopic Dermatitis

- A new peer-reviewed study published in *Lasers in Medical Science* validates that **STRATA Skin Sciences' XTRAC 308nm Excimer Laser combined with 0.1% tacrolimus ointment significantly improves outcomes for plaque-type psoriasis** patients compared to topical monotherapy.  **[1051514_2ec17a6f3e844957abb760b5205cb62a_0]** 
- The retrospective observational study, involving **100 adult patients**, showed the combination therapy group's mean PASI dropped from **18.36 to 3.30**, a statistically significant improvement over the monotherapy group.  **[1051514_2ec17a6f3e844957abb760b5205cb62a_0]** 
- This research reinforces the company's commitment to **personalized medicine** through individualized laser dosing and supports the XTRAC system's integration with other therapies.  **[1051514_2ec17a6f3e844957abb760b5205cb62a_0]** **[1051514_2ec17a6f3e844957abb760b5205cb62a_1]** 
- STRATA's President and CEO, Dr. Dolev Rafaeli, stated that this publication **adds weight to their case with CMS to expand reimbursement** for Excimer therapy.  **[1051514_2ec17a6f3e844957abb760b5205cb62a_1]**

STRATA Skin Sciences Announces New Study Validating XTRAC Excimer Laser Treatment

- STRATA Skin Sciences, Inc. announced a registered direct offering of **1,097,547 shares** of common stock at a purchase price of **$2.204 per share**.  **[1051514_0001213900-25-083709_ea025575601ex99-1_strata.htm:0]** **[1051514_0001213900-25-083709_ea0255756-8k_strata.htm:1]** 
- The offering is expected to generate approximately **$2.42 million** in gross proceeds, which the company intends to use for **working capital and general corporate purposes**.  **[1051514_0001213900-25-083709_ea025575601ex99-1_strata.htm:0]** **[1051514_0001213900-25-083709_ea0255756-8k_strata.htm:1]** 
- The closing of the offering is anticipated to occur on or about **September 4, 2025**, with Ladenburg Thalmann & Co. Inc. acting as the exclusive placement agent and receiving a **7.0% cash fee** of the gross proceeds plus up to **$50,000** in expense reimbursement.  **[1051514_0001213900-25-083709_ea025575601ex99-1_strata.htm:0]** **[1051514_0001213900-25-083709_ea0255756-8k_strata.htm:1]**

STRATA Skin Sciences Announces Pricing of Registered Direct Offering

- STRATA Skin Sciences (SSKN) announced its patent portfolio provides **intellectual property and market exclusivity** for combination therapies using its XTRAC excimer laser with JAK inhibitor, Systemic, and Biologic drugs.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** 
- The company holds **three key granted patents** (WO2021053673A1, US20220305282A1, US20220296919A1) that establish intellectual property rights for these combination therapies, which are expected to become standard of care for difficult-to-treat conditions.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** 
- These patents support expansion into new indications for inflammatory and autoimmune skin conditions, such as **vitiligo, atopic dermatitis, and alopecia areata**, in addition to psoriasis.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_1]** 
- The American Medical Association's CPT Editorial Panel approved updates to codes 96920–96922, expanding reimbursement eligibility for XTRAC treatments to these new conditions, effective **January 1, 2027**.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_1]**  STRATA aims to secure temporary CMS codes for reimbursement as early as the **2026 rule cycle**, potentially **tripling the addressable patient population**.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]** **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_1]** 
- The company is engaged in defensive litigation with LaserOptek, anticipating significant damages and injunctive relief.  **[1051514_cfc8f3888cf7498ea5aee260c906b7a1_0]**